PMID- 30262215
OWN - NLM
STAT- MEDLINE
DCOM- 20190104
LR  - 20190104
IS  - 1473-0502 (Print)
IS  - 1473-0502 (Linking)
VI  - 57
IP  - 5
DP  - 2018 Oct
TI  - Apheresis on aged patients/donors with complicated backgrounds like ischemic 
      heart disease, arrhythmia, and others.
PG  - 619-622
LID - S1473-0502(18)30355-0 [pii]
LID - 10.1016/j.transci.2018.09.006 [doi]
AB  - Peripheral blood stem cells (PBSCs) are currently one of the most important stem 
      cell sources for hematopoietic stem cell transplantation as well as cell therapy 
      for ischemic heart disease or critical limb ischemia. Thus, it is sometimes 
      necessary to collect autologous PBSCs from donors who have comorbidities. In 
      terms yield, a sufficient number of PBSCs can be collected from donors with 
      comorbidities for performing cell therapy if their age is < 60 years or up to a 
      maximum of 70 years, although the number of PBSCs collected from older donors 
      would probably be lower than that obtained from younger donors. On the other 
      hand, granulocyte colony-stimulating factor (G-CSF) administration sometimes 
      results in severe adverse events (AEs), such as ischemic heart disease and 
      vascular thrombosis. Therefore, it is very important to perform strict medical 
      check-ups according to the standards for donor operations in each country before 
      apheresis. The apheresis procedure and G-CSF administration should be performed 
      after administering the appropriate treatment. There is very less information 
      available regarding AEs related to citrate administration during apheresis in 
      aged donors with complicated medical histories. Medical staff should have 
      knowledge of the electrocardiogram (ECG) QTc prolongation that occurs during 
      apheresis owing to hypocalcemia caused by citrate administration, necessitating 
      electrocardiographic monitoring of patients. Calcium should be administered 
      during apheresis to prevent citrate related symptoms.
CI  - Copyright (c) 2018 Elsevier Ltd. All rights reserved.
FAU - Yokohama, Akihiko
AU  - Yokohama A
AD  - Transfusion Service, Gunma University Hospital, Faculty of Medicine, Gunma 
      University, Gunma, Japan. Electronic address: ayoko@gunma-u.ac.jp.
FAU - Yokote, Keiko
AU  - Yokote K
AD  - Transfusion Service, Gunma University Hospital, Faculty of Medicine, Gunma 
      University, Gunma, Japan; Division of Nursing, Gunma University Hospital, Faculty 
      of Medicine, Gunma University, Gunma, Japan.
FAU - Maruhashi, Takayuki
AU  - Maruhashi T
AD  - Transfusion Service, Gunma University Hospital, Faculty of Medicine, Gunma 
      University, Gunma, Japan.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20180918
PL  - England
TA  - Transfus Apher Sci
JT  - Transfusion and apheresis science : official journal of the World Apheresis 
      Association : official journal of the European Society for Haemapheresis
JID - 101095653
MH  - Aged
MH  - Arrhythmias, Cardiac/*therapy
MH  - Blood Component Removal/*methods
MH  - Female
MH  - Humans
MH  - Male
MH  - Myocardial Ischemia/*therapy
MH  - Tissue Donors
OTO - NOTNLM
OT  - Adverse event
OT  - Citrate acid
OT  - G-CSF
OT  - Limb ischemia
OT  - Myocardial infarction
OT  - Peripheral blood stem cell
EDAT- 2018/09/29 06:00
MHDA- 2019/01/05 06:00
CRDT- 2018/09/29 06:00
PHST- 2018/09/29 06:00 [pubmed]
PHST- 2019/01/05 06:00 [medline]
PHST- 2018/09/29 06:00 [entrez]
AID - S1473-0502(18)30355-0 [pii]
AID - 10.1016/j.transci.2018.09.006 [doi]
PST - ppublish
SO  - Transfus Apher Sci. 2018 Oct;57(5):619-622. doi: 10.1016/j.transci.2018.09.006. 
      Epub 2018 Sep 18.